This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (263)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Adherence  • Alert me on articles by topic

Diane Descamps, MD; Philippe Flandre, PhD; Vincent Calvez, MD, PhD; Gilles Peytavin, MD; Vincent Meiffredy, MD; Gilles Collin, MS; Constance Delaugerre, MD; Sandrine Robert-Delmas, MD; Brigitte Bazin, MD; Jean Pierre Aboulker, MD; Gilles Pialoux, MD; François Raffi, MD; Françoise Brun-Vézinet, MD, PhD; for the Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team

JAMA. 2000;283:205-211.

Context  In the Trilège trial, following induction with a zidovudine, lamivudine, and indinavir regimen, human immunodeficiency virus (HIV) replication was less suppressed by 2-drug maintenance therapy than by triple-drug therapy.

Objective  To identify mechanisms of virologic failure in the 3 arms of the Trilège trial.

Design  Case-control study conducted from February to October 1998.

Setting  Three urban hospitals in Paris, France.

Patients  Fifty-eight case patients with virologic failure (HIV RNA rebound to >500 copies/mL in 2 consecutive samples) randomized to 3 therapy groups: triple drug (zidovudine, lamivudine, and indinavir), 8; zidovudine-lamivudine, 29; and zidovudine-indinavir, 21; the case patients were randomly matched with 58 control patients with sustained viral suppression.

Main Outcome Measures  At virologic failure (S1 sample) and 6 weeks later (S2 sample), assessment of protease and reverse transcriptase gene mutations, plasma indinavir level, and degree of viral load rebound; pill count during induction and maintenance periods.

Results  Only 1 primary resistance mutation, M184V, was detected in S1 plasma samples from 4 of 6 patients in the triple-drug and in all 22 in the zidovudine-lamivudine therapy groups and in S2 plasma samples from 3 of 6 in the triple-drug and 20 of 21 in the zidovudine-lamivudine groups. Of controls, M184V was detected in 11 of 13 S1 plasma samples and in 10 of 11 S2 plasma samples. Indinavir levels were undetectable in all S1 samples but 2 in 7 triple-drug cases tested and in the expected range in 11 of 18 S1 and 5 of 12 S2 zidovudine-indinavir case plasma samples tested. Maintenance adherence rates were lower for cases vs controls for zidovudine (P = .05) and indinavir (P = .05). Low indinavir levels, lower adherence rates for zidovudine (P = .04) and lamivudine (P = .03), and rebound to near-baseline values suggested adherence as cause of early failure for 4 of 8 triple-drug cases. In the zidovudine-lamivudine arm, for which case and control adherence rates did not differ significantly (P = .96), most failures occurred late with low rebound, suggesting suboptimal drug potency. In the zidovudine-indinavir arm, virologic failures may be related to both mechanisms.

Conclusions  During the maintenance phase early and late virologic failures appeared to be related more to problems of adherence and antiretroviral treatment potency, respectively, than to selection of resistant mutant viruses.

Author Affiliations: Hôpital Bichat-Claude Bernard (Drs Descamps, Peytavin, and Brun-Vézinet and Mr Collin), Hôpital Pitié-Salpétrière (Drs Calvez and Delaugerre), and Hôpital Rothschild, (Dr Pialoux), Paris; INSERM-Service Commun 10, Villejuif (Drs Flandre, Meiffredy, Robert-Delmas, Bazin, and Aboulker); and Hôpital de l'Hôtel Dieu, Nantes (Dr Raffi), France.

RELATED ARTICLES

Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens
Diane V. Havlir, Nick S. Hellmann, Christos J. Petropoulos, Jeannette M. Whitcomb, Ann C. Collier, Martin S. Hirsch, Pablo Tebas, Jean-Pierre Sommadossi, and Douglas D. Richman
JAMA. 2000;283(2):229-234.
ABSTRACT | FULL TEXT  

Resistance, Fitness, Adherence, and Potency: Mapping the Paths to Virologic Failure
Martin Markowitz
JAMA. 2000;283(2):250-251.
EXTRACT | FULL TEXT  

January 12, 2000
JAMA. 2000;283(2):273-274.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Forgiveness of non-adherence to HIV-1 antiretroviral therapy
Shuter
J Antimicrob Chemother 2008;61:769-773.
ABSTRACT | FULL TEXT  

A Prospective Study of Adherence and Virologic Failure in HIV-Infected Patients: Role of a Single Determination of Plasma Levels of Antiretroviral Medications
Cuevas Gonzalez et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:245-250.
ABSTRACT  

Hospital-Based Directly Observed Therapy for HIV-Infected Children and Adolescents to Assess Adherence to Antiretroviral Medications
Glikman et al.
Pediatrics 2007;119:e1142-e1148.
ABSTRACT | FULL TEXT  

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
Tenney et al.
Antimicrob. Agents Chemother. 2007;51:902-911.
ABSTRACT | FULL TEXT  

Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2006;296:827-843.
ABSTRACT | FULL TEXT  

In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection
Gu et al.
Antimicrob. Agents Chemother. 2006;50:625-631.
ABSTRACT | FULL TEXT  

Barriers to Antiretroviral Medication Adherence in Young HIV-Infected Children
Roberts
Youth Society 2005;37:230-245.
ABSTRACT  

Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Wainberg et al.
Antimicrob. Agents Chemother. 2005;49:1671-1678.
FULL TEXT  

A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients
Monie et al.
J. Virol. 2005;79:5185-5202.
ABSTRACT | FULL TEXT  

Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification
Martinez-Picado et al.
J. Clin. Microbiol. 2005;43:436-438.
ABSTRACT | FULL TEXT  

Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture
Petrella et al.
Antimicrob. Agents Chemother. 2004;48:4189-4194.
ABSTRACT | FULL TEXT  

Nonadherence With Pediatric Human Immunodeficiency Virus Therapy as Medical Neglect
Roberts et al.
Pediatrics 2004;114:e346-e353.
ABSTRACT | FULL TEXT  

HIV Drug Resistance
Clavel and Hance
NEJM 2004;350:1023-1035.
FULL TEXT  

Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1
Zhang et al.
J. Virol. 2004;78:1718-1729.
ABSTRACT | FULL TEXT  

Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations
de Mendoza et al.
J. Clin. Microbiol. 2004;42:862-866.
ABSTRACT | FULL TEXT  

Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine
Bocket et al.
J Antimicrob Chemother 2004;53:89-94.
ABSTRACT | FULL TEXT  

Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1
Turner et al.
J Antimicrob Chemother 2004;53:53-57.
ABSTRACT | FULL TEXT  

Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Shafer et al.
NEJM 2003;349:2304-2315.
ABSTRACT | FULL TEXT  

Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1
Turner et al.
CVI 2003;10:979-981.
FULL TEXT  

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors
Colonno et al.
Antimicrob. Agents Chemother. 2003;47:1324-1333.
ABSTRACT | FULL TEXT  

Efficacy and Toxicity of Antiretroviral Therapy Using 4 or More Agents: Application of a Strategy for Antiretroviral Management in Human Immunodeficiency Virus-Infected Children
Melvin et al.
Arch Pediatr Adolesc Med 2002;156:568-573.
ABSTRACT | FULL TEXT  

Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase
Van Rompay et al.
J. Virol. 2002;76:6083-6092.
ABSTRACT | FULL TEXT  

Full Adherence to HAART: Is It Really Necessary?
Cainelli et al.
Arch Intern Med 2002;162:944-945.
FULL TEXT  

Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression
Jacobson et al.
Am J Epidemiol 2002;155:760-770.
ABSTRACT | FULL TEXT  

Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Shafer
Clin. Microbiol. Rev. 2002;15:247-277.
ABSTRACT | FULL TEXT  

Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
Maguire et al.
Antimicrob. Agents Chemother. 2002;46:731-738.
ABSTRACT | FULL TEXT  

Evaluation and Management of HIV-Infected Women
Levine
ANN INTERN MED 2002;136:228-242.
ABSTRACT | FULL TEXT  

Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
Nieuwkerk et al.
Arch Intern Med 2001;161:1962-1968.
ABSTRACT | FULL TEXT  

HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
Hermankova et al.
JAMA 2001;286:196-207.
ABSTRACT | FULL TEXT  

Mathematical biology and medical statistics: contributions to the understanding of AIDS epidemiology
Donnelly and Cox
Stat Methods Med Res 2001;10:141-154.
ABSTRACT  

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults: A Randomized Equivalence Trial
Staszewski et al.
JAMA 2001;285:1155-1163.
ABSTRACT | FULL TEXT  

The Pills Identification Test: A Tool to Assess Adherence to Antiretroviral Therapy
Parienti et al.
JAMA 2001;285:412-412.
FULL TEXT  

Antiretroviral resistance during successful therapy of HIV type 1 infection
Martinez-Picado et al.
Proc. Natl. Acad. Sci. USA 2000;97:10948-10953.
ABSTRACT | FULL TEXT  

Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug
Mammano et al.
J. Virol. 2000;74:8524-8531.
ABSTRACT | FULL TEXT  

Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance
Mouroux et al.
J. Clin. Microbiol. 2000;38:2726-2730.
ABSTRACT | FULL TEXT  

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel
Hirsch et al.
JAMA 2000;283:2417-2426.
ABSTRACT | FULL TEXT  

Adherence Critical to Sustaining Viral Suppression in HIV Treatment
JWatch Infect. Diseases 2000;2000:3-3.
FULL TEXT  

Check Adherence before Switching Drugs
AIDS Clin Care 2000;2000:6-6.
FULL TEXT  

The Case for More Cautious, Patient-Focused Antiretroviral Therapy
Henry
ANN INTERN MED 2000;132:306-311.
ABSTRACT | FULL TEXT  

Resistance, Fitness, Adherence, and Potency: Mapping the Paths to Virologic Failure
Markowitz
JAMA 2000;283:250-251.
FULL TEXT